Intrommune Therapeutics

Intrommune Therapeutics is a clinical-stage biotechnology company focused on developing patient-friendly treatment platforms for food allergies. The company's core technology, Oral Mucosal Immunotherapy (OMIT), utilizes patented biochemical processes to stabilize and deliver allergenic proteins in a fully functional toothpaste. This approach allows for the convenient administration of immunotherapy during a patient's daily toothbrushing routine, aiming to desensitize the immune system to specific food allergens. The company's lead product candidate, INT301, is designed for the treatment of peanut allergies. Intrommune has successfully completed a Phase 1 clinical trial (the OMEGA study) in adults, which demonstrated safety and tolerability. The company is currently focused on advancing its pipeline, including pediatric studies and potential expansion into other food allergies.